Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash from Financing Activities (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Cash from Financing Activities for 17 consecutive years, with $24.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 440.45% to $24.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.3 million through Dec 2025, down 88.09% year-over-year, with the annual reading at $28.3 million for FY2025, 88.09% down from the prior year.
  • Cash from Financing Activities hit $24.3 million in Q4 2025 for Integra Lifesciences Holdings, up from -$10.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $358.7 million in Q1 2024 to a low of -$162.7 million in Q1 2023.
  • Historically, Cash from Financing Activities has averaged -$15.7 million across 5 years, with a median of -$10.5 million in 2023.
  • Biggest five-year swings in Cash from Financing Activities: crashed 18852.21% in 2022 and later soared 440.45% in 2025.
  • Year by year, Cash from Financing Activities stood at $521000.0 in 2021, then plummeted by 18852.21% to -$97.7 million in 2022, then skyrocketed by 92.95% to -$6.9 million in 2023, then dropped by 3.77% to -$7.2 million in 2024, then skyrocketed by 440.45% to $24.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for IART at $24.3 million in Q4 2025, -$10.2 million in Q3 2025, and -$21.1 million in Q2 2025.